Cutaneous Lupus Erythematosus (CLE) Treatments

Find Cutaneous Lupus Erythematosus (CLE) Treatments

Generic Name

Hydroxychloroquine

Brand Names

Plaquenil, Sovuna

FDA approval date: January 03, 2008

Classification: Antimalarial

Form: Tablet

What is Plaquenil (Hydroxychloroquine)?

Hydroxychloroquine sulfate tablets is an antimalarial and antirheumatic indicated for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma Through Image-guided Locoregional Therapy

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemotherapeutics and then blocking the artery with embolics in order to kill tumor cells by depriving them of essential oxyge...

A Phase II Trial of Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY)

Who is this study for: Patients with ER+/Her2 neg invasive breast cancer with no evidence of recurrent local or distant disease

Enrollment Status: Recruiting

Publish Date: April 09, 2026

Intervention Type: Drug

Study Drugs: Hydroxychloroquine, Avelumab, Palbociclib

Study Phase: Phase 2

Summary: This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Who is this study for: Patients with Multiple Sclerosis

Enrollment Status: Recruiting

Publish Date: April 06, 2026

Intervention Type: Drug

Study Drugs: Pioglitazone, Clemastine Fumarate, Hydroxychloroquine, Dantrolene

Study Phase: Phase 1/Phase 2

Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers. They want to see if a change in biomarker levels can predict which drugs a person with MS might respond to.

View All Clinical Trials